← Back to all trials
Not Yet Recruiting
NCT07782333
A Study Evaluating TRIV-573 in Atopic Dermatitis
Conditions: Atopic Dermatitis
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 90
Sponsor: Triveni Bio
Summary
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).
The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Eligibility Criteria
Inclusion Criteria:
* Has Atopic Dermatitis.
* Has moderate to severe, active and symptomatic atopic dermatitis.
Exclusion Criteria:
* Severe or uncontrolled medical conditions.
* Use of prohibited medications within stated washout periods.
Source: ClinicalTrials.gov (NCT07782333). StuddyBuddy aggregates publicly available trial information.
